Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–308 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, AEGR-733; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 5
States / cities: Pinellas Park, Florida • Edina, Minnesota • Mogadore, Ohio + 2 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Adalimumab, Lisinopril, losartan, and atorvastatin, galactose; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 1 Year to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 17
States / cities: Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more

Conditions: Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 39
States / cities: Anaheim, California • Huntington Beach, California • Los Angeles, California + 36 more

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sleep Apnea, Obstructive
Interventions: Atorvastatin, Placebo oral capsule; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Carcinoma, Ulcerative Colitis
Interventions: Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Kansas City, Kansas

Conditions: Hypercholesterolemia
Interventions: LY3015014, Placebo, Statin, Ezetimibe; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Encino, California • Lancaster, California • Spring Valley, California + 12 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, PF-04950615 (RN316); Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more

Conditions: Endometriosis
Interventions: Atorvastatin; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Coarctation of the Aorta
Interventions: atorvastatin, Sugar pill; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity
Interventions: Danuglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Anaheim, California • South Miami, Florida

Conditions: Healthy
Interventions: Enlicitide Decanoate, Atorvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes
Interventions: Atorvastatin, Rosuvastatin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Liver Fibroses, Cirrhosis
Interventions: Atorvastatin 20mg, Placebo; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more

Conditions: Mild Cognitive Impairment
Interventions: Atorvastatin Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Lymphoma, Non-Hodgkin
Interventions: Atorvastatin; Drug
Lead sponsor: Dean Felsher; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Conditions: Hyperlipidemia
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 23
States / cities: Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more

Conditions: Hypertension
Interventions: Amlodipine and Hydrocholorothiazide; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

Statins and CPAP in Adipose Tissue of OSA

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

A Study of LY3015014 in Participants With High Cholesterol

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

Statins and Endothelial Function in Patients With Coarctation of the Aorta

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.